+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Gonorrhea Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4896261
  • Report
  • January 2020
  • Region: Global
  • 110 pages
  • Mordor Intelligence
UP TO OFF
until Mar 31st 2020
1 of 4

FEATURED COMPANIES

  • Allergan, Inc.
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Lupin Pharmaceuticals
  • Pfizer Inc.
  • Teligent, Inc.
  • MORE
Market Overview

Gonorrhea is an infection caused by a sexually transmitted bacterium that infects both males and females. The primary factors such as the rising prevalence of gonorrhea, implementation of national screening programs and growing public awareness are propelling the growth of the gonorrhea therapeutics market. According to the Centers for Disease Control and Prevention (CDC), around 700,000 new cases of gonorrhea are detected each year. In 2019, the National Institute of Allergy and Infectious Diseases (NIAID) has granted USD 41.6 million over five years to support collaborative, multidisciplinary research on the bacteria that cause syphilis, gonorrhea, and chlamydia. Thus, with the growing prevalence of STDs increases patient awareness through national campaigns and growing government initiatives are anticipated to drive market growth.

However, stringent regulatory scenarios and social stigma associated with patients visiting STD clinics are expected to restrain the growth of the global market in the forecast period.

Scope of the Report

As per the scope of the report, gonorrhea is a common sexually transmitted disease (STD) caused by a bacterium Neisseria gonorrhoeae (Gc) that result in serious complications if not detected and treated.

Key Market Trends

Dual Therapy Segment is Expected to Register Good Growth Over the Forecast Period

By Treatment, the market has been segmented into monotherapy and dual therapy. Gonorrhea, caused by Neisseria gonorrhoeae, is the second most common bacterial STI and results in substantial morbidity. The dual therapy segment is estimated to dominate the global market, and this trend is expected to continue over the forecast period. Dual therapy with ceftriaxone and azithromycin is recommended as the first-line regimen for the treatment of gonorrhea. WHO recommends dual therapy over monotherapy for people with symptomatic and asymptomatic gonorrhea. Also, monotherapy is no longer a viable option in many settings worldwide. In addition, growing public awareness and a large patient pool also contribute to the growth of the gonorrhea therapeutics market.

North America is Estimated to Lead the Gonorrhea Therapeutics Market

North America is expected to lead the market, owing to high standards of healthcare infrastructure and easy availability of sophisticated technology in this region. As per CDC estimates, in 2018 around 583,405 cases of gonorrhea were reported in the United States. However, Europe and the Asia Pacific are followed next after North America owing to the increasing incidence of gonococcal infection, and the rise in collaboration of domestic and international companies in these regions. For instance, In 2019, Binx health announced that its proprietary Chlamydia and Gonorrhea (CT/NG) test has received European CE Mark approval, which is expected to drive the gonorrhea therapeutics market in the forecast period.

Competitive Landscape

The major players in the gonorrhea therapeutics market include Allergan, Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Lupin Pharmaceuticals, Pfizer Inc, Teligent, Inc., among others.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Allergan, Inc.
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Lupin Pharmaceuticals
  • Pfizer Inc.
  • Teligent, Inc.
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Gonorrhea
4.2.2 Growing Government and Private Sector Participation Through National Campaigns
4.3 Market Restraints
4.3.1 Stringent Regulatory Scenario
4.3.2 Social Stigma Associated With Patients Visiting STD Clinics
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Gonococcal Infection
5.1.1 Uncomplicated Gonococcal Infection
5.1.2 Gonococcal Arthritis
5.1.3 Gonococcal Meningitis and Endocarditis
5.2 By Treatment
5.2.1 Monotherapy
5.2.2 Dual Therapy
5.3 By End User
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Online Pharmacies
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Allergan, Inc.
6.1.2 F. Hoffmann-La Roche Ltd
6.1.3 GlaxoSmithKline plc
6.1.4 Lupin Pharmaceuticals
6.1.5 Pfizer Inc.
6.1.6 Teligent, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Allergan, Inc.
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Lupin Pharmaceuticals
  • Pfizer Inc.
  • Teligent, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll